<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440892</url>
  </required_header>
  <id_info>
    <org_study_id>Survivin in Treatment</org_study_id>
    <nct_id>NCT03440892</nct_id>
  </id_info>
  <brief_title>Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients</brief_title>
  <acronym>SurviTreat</acronym>
  <official_title>Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the utility of survivin as a biomarker of pharmacological response to therapeutic
      intervention in rheumatoid arthritis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective observational study the investigators aim to study the ability of modern
      antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis
      patients scheduled to start new pharmacological treatment will be followed for a period of 6
      months. No intervention or influence on choice of treatment will be performed, the decision
      of new/other medication is entirely made by the patient and their rheumatologist. The study
      entails addition of survivin analyse (1 vial of sera) before and after start of new
      treatment. Data concerning survivin levels, disease activity and other clinical parameters
      before and after start of new treatment will also be analysed. The patients will leave sera
      for survivin analyse at baseline and 3 and 6 months after start of new treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survivin status</measure>
    <time_frame>6 months</time_frame>
    <description>Patients with a survivin level of over 0.45 ng/ml are considered to be survivin positive.
Patients with survivin levels under 0.45 ng/ml are considered to be survivin negative
A change from survivin positive to survivin negative (or vice versa) equals conversion of survivin status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity (DAS28)</measure>
    <time_frame>6 months</time_frame>
    <description>Disease activity, DAS28, is calculated using a specific formula based on:
number of painful joints from 28 joints
number of swollen joints from 28 joints
erythrocyte sedimentation rate (ESR) or C reactive protein (CRP)
patient's global assessment of disease activity on a 100 mm visual analogue scale (VAS)
DAS thresholds:
DAS28 below 3.2: low disease activity DAS28 over 3.2 and under 5.1: moderate disease activity DAS28 above 5.1: high disease activity DAS28 lower than 2.6: remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The EULAR response criteria classify patients as good, moderate, or non-responders, using the change in DAS28 and the level of DAS28 reached. A patient must show a significant change as well as low disease activity to be classified as a good responder.
Good responder: DAS28 scores ≤ 3.2 with reductions in DAS28 &gt;1.2 Moderate responder: DAS28 scores &gt; 3.2 with reductions in DAS28 &gt;1.2 Non-responder: reductions in DAS28 ≤ 0.6</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>folate antagonist</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfasalazine</intervention_name>
    <description>Immunomodulatory</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Salazopyrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab</intervention_name>
    <description>IL-6 receptor antagonist</description>
    <arm_group_label>1</arm_group_label>
    <other_name>RoActemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib/baricitinib</intervention_name>
    <description>JAK inhibitor</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xeljanz/Olumiant</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the RA classification criteria according to the ACR/EULAR

        Exclusion Criteria:

          -  Patients at stable/unchanged anti-rheumatic treatment

          -  Other serious physical or mental illness

          -  Lack of knowledge in Swedish making answering the questionnaires impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Bokarewa, MD</last_name>
    <email>maria.bokarewa@rheuma.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Rheumatology and Inflammation research</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia T Silfverswärd</last_name>
      <email>sofia.silfversward@rheuma.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>survivin</keyword>
  <keyword>biomarker of pharmacological response</keyword>
  <keyword>antirheumatic treatment</keyword>
  <keyword>methotrexate</keyword>
  <keyword>sulfasalazin</keyword>
  <keyword>abatacept</keyword>
  <keyword>tocilizumab</keyword>
  <keyword>tofacitinib/baricitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

